SMMT Q3 2025 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$42,000

Operating Income

-$234M

Net Income

-$232M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$95M

Free Cash Flow

-$95M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$262M

Total Liabilities

$69M

Stockholders' Equity

$192M

Cash & Equivalents

$239M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$42,000	-$19,999	-110.0%
Operating Income	-$234M	-$58M	-303.0%
Net Income	-$232M	-$56M	-312.0%